Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Alterity Therapeutics Ltd. ( (AU:ATH) ) is now available.
Alterity Therapeutics announced a successful capital raising of A$40 million through a two-tranche placement supported by both domestic and international investors. The funds will primarily advance the development of ATH434, a promising treatment for neurodegenerative diseases, particularly Multiple System Atrophy (MSA). The company plans to engage with the FDA to accelerate ATH434’s development, motivated by positive Phase 2 trial results showing significant slowing of MSA progression and a favorable safety profile. This capital injection strengthens Alterity’s financial position, allowing further research and development in neurodegenerative diseases, including Parkinson’s Disease.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. Its lead product, ATH434, is aimed at treating Parkinsonian disorders and is being evaluated in clinical trials for Multiple System Atrophy.
Average Trading Volume: 100
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $41.31M
For detailed information about ATH stock, go to TipRanks’ Stock Analysis page.